Fosamax and Osteonecrosis of the Jaw: Examining the Evidence for Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health and Science Information

The Immunodeficiency Foundation’s archival mission has long centered on the broad dissemination of general health and science information, with a particular emphasis on the historical evolution of medical understanding. This legacy includes documenting how public health narratives shift as new clinical observations emerge, particularly when widely prescribed therapies are linked to unexpected adverse events. Within this tradition, the Foundation has maintained records tracing the trajectory of bisphosphonate medications—originally developed for bone density management—from their introduction into mass production to their widespread clinical adoption. Over time, accumulated case reports and epidemiological data have prompted a reevaluation of their risk profile, especially regarding long-term exposure. This pivot from general health education to a more focused occupational concern arises naturally from the Foundation’s archival scope: as manufacturing processes scaled up, so too did the population of patients receiving sustained therapy. The transition from a broad informational context to a specific exposure concern is therefore not a departure from the Foundation’s mission, but rather a logical extension of its commitment to documenting the evolving interface between therapeutic innovation and patient safety. This shift necessitates a careful examination of exposure parameters, without venturing into mechanistic speculation, to better understand the conditions under which risk may be elevated.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the Foundation's archival commitment to tracking therapeutic innovations and their safety profiles, we now focus on Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but more commonly associated with dental procedures such as tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, infection, and exposed bone in the jaw. Diagnosis relies on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis. The condition has been reported in patients taking bisphosphonates, including Fosamax, and is recognized as a known risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are thought to involve the drug's potent inhibition of osteoclast-mediated bone resorption. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and may suppress normal bone remodeling, leading to microdamage accumulation and impaired healing. This is supported by multiscale characterization of jawbone, which provides information on jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, the anti-angiogenic properties of bisphosphonates may reduce blood supply to the jaw, further compromising tissue viability. Risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4, "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that ONJ can occur spontaneously and is generally associated with tooth extraction or local infection with delayed healing. Known risk factors are listed, and it is advised that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the warning does not specify a precise timeline for onset, and the time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates causation assessment for affected patients. Causation-related considerations for patients who develop ONJ after Fosamax use involve evaluating the temporal relationship between drug exposure and symptom onset, as well as the presence of other risk factors. The label notes that in placebo-controlled clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that ONJ is not a common adverse event in the general osteoporosis population. However, the association is established through postmarketing reports and case series. For affected patients, the timeline between exposure and documented harm can range from days to months, and a subset of patients may experience recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients have relief of symptoms after discontinuing the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), supporting a causal link. In summary, while Fosamax is effective for osteoporosis and Paget's disease, it carries a known risk of ONJ, particularly in patients with additional risk factors. The prescribing information provides warnings and risk mitigation strategies, but the variable onset and multifactorial nature of ONJ require careful clinical evaluation for each affected patient.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ) in postmarketing reports. ONJ is a condition of exposed, non-healing bone in the jaw, often triggered by dental procedures or local infection. The prescribing information includes a warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and comorbidities like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Longer duration of bisphosphonate exposure may increase risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is causation assessed for ONJ in Fosamax users?

Causation assessment involves evaluating the temporal relationship between drug exposure and symptom onset, considering other risk factors. The time to onset can vary from days to months. Most patients improve after discontinuation, supporting a causal link, but the label notes similar symptom rates in placebo groups in clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.